First-ever commercial diagnostic test for deadly equine virus now available

 NEV is a horse equivalent of HIV and is becoming an increasingly serious threat to at least 10 percent of the global horse population.To counter this emerging threat, Equigerminal Team has launched a crowdfunding campaign to raise funds.

New Equine Virus or NEV is a horse equivalent of HIV and is becoming an increasingly serious threat to at least 10 percent of the global horse population.

 To counter this emerging threat, Equigerminal Team has launched a crowdfunding campaign to raise funds and support for the development of tests and antivirals to control this threat. The team of scientists is now welcoming everyone to generously support this campaign.

The team is offering NEV tests as a reward for the backers and more details are available on the Indiegogo campaign page of the project.A veterinarian is required to take the horse’s blood, which is sent to the Equigerminal lab where it is tested and then results sent

New Equine Virus (NEV) was first identified in 2013 by Isabel Fidalgo Carvalho and Alexandre Pires. Isabel and Alexandre went on to found Portugal-based equine biotech firm Equigerminal in order to develop an accurate and commercially viable NEV diagnostic test.

We have spent the last five years developing a diagnostic test and a potential cure for NEV”, explains Pires. “We now need to raise awareness of the problem and help vets to diagnose this disease correctly.”

A diagnostic test, able to identify a deadly virus believed to be present in up to 10% of horses, is now available for the first time for horse lovers.

Our world is interconnected
'The greatest danger to our future is apathy' for animal diseases and the spread of virus with zoonotic potential!
ACT against a new deadly equine virus, similar to HIV.”

— Isabel Carvalho

COIMBRA, COIMBRA, PORTUGAL, July 16, 2018 /EINPresswire.com/ — Equigerminal is an established biotech company specialising in equine health. It already offers more than 60 lab-testing services to horse owners and vets.
Equigerminal hopes to develop further equine healthcare and welfare products and services, such as DNA testing services and pathogen screening to aid the world’s almost 70 million horses.

New Equine Virus or NEV is a horse equivalent of HIV and is becoming an increasingly serious threat to at least 10 percent of the global horse population. To counter this emerging threat, Equigerminal Team has launched a crowdfunding campaign to raise funds and support for the development of tests and antivirals to control this threat. The team of scientists is now welcoming everyone to generously support this fundraising campaign and their goal is to raise a sum of EUR 15,000.

New Equine Virus (NEV) was first identified in 2013 by Isabel Fidalgo Carvalho and Alexandre Pires. Isabel and Alexandre went on to found Portugal-based equine biotech firm Equigerminal in order to develop an accurate and commercially viable NEV diagnostic test that can be used by vets, vet labs and horse owners.

After many years of research and testing the diagnostic test is now launching to the equine community.

NEV – the equine equivalent of HIV – is often misdiagnosed or hidden by other diseases that induce similar symptoms, like anemia and neurological issues in horses. It is most commonly confused with the West Nile Virus, Swamp Fever virus (EIAV) and Equine Herpesviruses (EHV)

Horses thought to have the highly-contagious Swamp Fever can be ordered to be culled by officials in an attempt to stop its spread – a tragedy for the horses, and highly distressing and costly for owners.

By testing a number of horses with anemia Equigerminal researchers first believed they had found the presence of a divergent strain of the Swamp Fever Virus (EIAV) – because the horses cross reacted with EIAV, but were negative in the official tests (the Coggins test). But subsequent research found they were actually suffering from NEV

NEV, which can lead to severe neurological diseases and also prove fatal, can now be identified through the use of the new diagnostic test developed by Equigerminal.

A veterinarian is required to take the horse’s blood, which is sent to the Equigerminal lab where it is tested and then results are returned to the owner/vet.

Once the horse has been tested the appropriate treatment can be given and the spread of the disease prevented. The treatment is currently targeted towards improving the general well-being of the horse, health monitoring, and boosting the animal’s immune system. The next stage is to find a treatment, and ideally a cure for NEV.

NEV was discovered by Portuguese scientist, veterinarian and entrepreneur Isabel Fidalgo Carvalho while completing her PhD in Equine Sciences at the Universities of Oporto and Pittsburgh.

“During my time at University and at Equigerminal, I noticed unusual anemia and severe neurological signs in horses, which in my PhD I wrongly hypothesized to be attributed to Swamp Fever”, says Carvalho.

“I realized through the samples that this virus was actually closer to equine HIV – New Equine Virus, or NEV”.

Carvalho launched Equigerminal in 2011 with fellow equine scientist, inventor and entrepreneur, Alexandre Vieira Pires.

“We have spent the last five years developing a diagnostic test and a potential cure for NEV”, explains Pires.

“We now need to raise awareness of the problem and help vets to diagnose this disease correctly.”

Equigerminal hopes to develop further equine healthcare and welfare products and services, such as DNA testing services and pathogen screening to aid the world’s almost 70 million horses.

New Equine Virus or NEV is a horse equivalent of HIV and is becoming an increasingly serious threat to at least 10 percent of the global horse population. To counter this emerging threat, Equigerminal Team has launched a crowdfunding campaign to raise funds and support for the development of tests and antivirals to control this threat. The team of scientists is now welcoming everyone to generously support this fundraising campaign and their goal is to raise a sum of EUR 15,000.

The Indiegogo Campaign is located on the web at:
www.indiegogo.com/projects/equigerminal-pets and supporters from around the world can back this project by making generous pledges and donations. Everyone, especially pet lovers and those who care about saving a major chunk of horse population are welcomed to participate in the fundraising. The team is offering NEV tests as a reward for the backers and more details are available on the Indiegogo campaign page of the project.

About This Project
Equigerminal is a horse biotech company based in Europe and it has recently discovered a new lentivirus that affects horses. The new virus is called New Equine Virus (NEV) and it is a serious threat to the horse population worldwide. The team of scientists is now raising funds and support to counter this threat via Indiegogo and it is welcoming everyone for generous community backing.

Isabel Carvalho
Equigerminal SA
239094666
email us here

We’ve identified a New Equine Virus, similar to HIV, developed tests and antivirals to control it.


Source: EIN Presswire

Dr. Srini Pillay, Reveals 5 Counterintuitive Ways to Benefit From Psychotherapy

Dr. Srini Pillay

New research helps explain why unfocus can help you in therapy.

LOS ANGELES, CA, UNITED STATES, July 13, 2018 /EINPresswire.com/ — Dr. Srini Pillay, best-selling author of TINKER DABBLE DOODLE TRY, aptly reveals five counterintuitive ways of benefitting from psychotherapy.

“Most people request psychotherapy for a reason. Either they are overwhelmed by their own emotions or thoughts, or they have mental roadblocks that they have to navigate,” Pillay shares. “Often, people come in expecting that they will focus on their goals. But much of the value of psychotherapy actually lies in unfocusing.”

Lesson #1: “Goals” are far less obvious than they seem. When we say we have a goal, we may simply be reporting what our brains have already decided. Deeper thought may reveal that this is not what we truly want. The real goal may be obscure, so you may want to question and examine your actual goals from time to time.

Lesson #2: When you are logical, you may succumb to habit pathways in the brain. This will not help you get unstuck. One way to overcome this is to allow your mind to wander. This kind of unfocusing will turn on more “self” representations in the brain. You feel more self-connected. As a result, you will be more likely to find creative solutions to your problems.

Lesson #3: Your brain is a little like a telephone. Sometimes you may be in sync with your therapist; at other times, not. Either way, it’s helpful to look at those feelings in the interaction and not just what comes from you.

Lesson #4: Being practical is not always the best thing. Also, becoming intolerant of ambiguity and uncertainty could rob you of the power of your paradoxes, sterilizing you and removing the motivation that authenticity can bring when you are holding contradictory feelings.

Lesson #5: When therapists are reflective out loud, detailing even minutiae, it may seem that they are off track. They wouldn’t be remembering their story if you had not contributed to it. Called reverie, this could be something to explore instead of reject or ignore.

“In all of these suggestions, unfocus is key. Unfocusing from your goals, releasing the hold of logic, looking outside yourself, and opening your mind to the therapist’s rambling are all things you might want to try out,” Pillay expertly concludes.

Aurora DeRose
Aurora DeRose
310-396-6090
email us here


Source: EIN Presswire

SMi’s Biosimilars & Biobetters Exclusive Interview with expert speaker Dr Michel Mikhail released

Biosimilars & Biobetters 2018

SMi Reports: An exclusive interview with Dr Michel Mikhail, who is chairing Biosimilars & Biobetters event, is now available to download on the event website.

LONDON, LONDON, UNITED KINGDOM, July 13, 2018 /EINPresswire.com/ — SMi Group recently caught up with expert speaker Dr Michel Mikhail, International Expert in Regulatory Affairs and Global Expert in Biosimilars, in the run up to the 9th annual conference on Biosimilars & Biobetters, taking place 26th – 27th September 2018 in London, UK.

Dr Mikhail has more than 25 years’ experience in the Pharmaceutical Industry and a track record
of achievement in R & D and International Regulatory Affairs in large multinational, research-based
pharmaceutical and biotech companies, as well as in the generic industry. He has been involved in the global development and worldwide regulatory approval of Blockbuster Monoclonal antibodies medicines, as well as shaping the EU Biosimilars Guidelines and their review, the WHO Guidelines, ICH Guidelines and recently the US-FDA Biosimilars Guidelines.

He is a chartered expert in pharmacology-toxicology, a chartered clinical expert, as well as a chartered analytical expert. Dr Mikhail served on the safety working group and efficacy working group of the European Federation of pharmaceutical Industry associations (EFPIA), and as a topic
leader. Dr Mikhail is a member of the expert committee of the Government Federal Institute of Risk Assessment (BfR) Germany and served as a member of the Expert Committee for Toxicology of the
United States Pharmacopoeia (USP).

Interview Snapshot:

1. What are the key areas for improvement within the industry?

There are not very many biosimilars companies that understand the US market and the correct market entry strategy. Each Market is different, the EU market where Pricing and Reimbursement is within the National competencies and is not regulated on EU level. The US having a two-step approval process: the first one is approval as a Biosimilar and the second step is approval as an interchangeable biosimilar with a one-year exclusivity for the first interchangeable biosimilar. Companies need to better understand the corresponding market and then set and execute tier development and regulatory strategy.

2. What current hot topic will you be addressing in your presentation and what would you say makes it relevant to 2018?

I’ll address the ‘US-FDA interchangeability guidance – what is needed to obtain the interchangeable status for the biosimilar product’. This is a very hot topic in view of the Draft US-FDA Guidance published in January 2017. The audience will hear about the latest FDA regulatory changes towards interchangeability of biosimilars.

• Evaluation of biosimilars in the race to obtaining this status
• First in line: recommendations on how to achieve interchangeability and succeed obtaining 12 months exclusivity as first interchangeable biosimilar.
• Discuss what will need to be done after accomplishing this to increase biosimilar uptake in patients, physicians and prescribers’ groups and non-the less the success and profitability of the Biosimilar developing company.

The full interview is available to download on the event website, where you can also view the latest agenda and speaker line-up. Potential attendees can take advantage of the summer special £200 discount using the voucher code BIOUK200OFF. Please visit the website for more information and to register: www.biosimilars-europe.com/pr2

Interested in sponsoring, exhibiting or speaking at this event?
Please contact Alia Malick on +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk.

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

Biosimilars and Biobetters
26th – 27th September 2018
Copthorne Tara Hotel, Kensington, London, UK
www.biosimilars-europe.com/pr2

—- END —-

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
02078276000
email us here


Source: EIN Presswire

German TV show features mission of Alzheimer’s Germ Quest, Inc., reports Dr. Leslie Norins, CEO

German news show profiles American couple offering $1 million to any scientist who can prove a germ triggers Alzheimer's.

The volume of media inquiries we received attests to the fact that the public is now demanding fresh approaches to AD research be funded.”

— Dr. Leslie Norins

NAPLES, FL, UNITED STATES, July 13, 2018 /EINPresswire.com/ — The popular German TV show, Nano, on 3 SAT, which some liken to America’s “60 Minutes”, recently presented as its lead segment an interview with Leslie Norins, MD, PhD, CEO of Alzheimer’s Germ Quest, Inc. (AGQ), and his wife Rainey, Vice President, discussing the possibility that germs might play a role in the causation of Alzheimer’s disease (AD).

Several months ago, the German show’s producers became interested in fresh thinking about the possible triggers of AD and spotted a news item about the launch of AGQ’s project to help accelerate and deepen research on the likely participation of infectious agents. They sent a film crew to Naples for a detailed interview of the Norins’.

The entourage also went to a local senior center to observe and film how it conducts half-day classes, such as arts and crafts, for Alzheimer’s patients, so as to provide respite for their caregivers. The great impact made by meeting the patients led AGQ to propose the creation of “boot camps” to expose new AD researchers to the cognition deterioration the AD process inflicts on formerly vibrant seniors.

The German film crew remarked on how “open” American families were about a member’s having AD. They said that sometimes in Germany there is a kind of shame associated with the diagnosis, and so it is kept veiled in some cases.

Dr. Norins said that following the show’s broadcast in Germany, numerous emails were received from viewers there. He took this as a sign citizens there were as eager for research progress as those in the U.S.
Dr. Norins believes this show, and numerous other media inquiries he has received attest to the fact that the public is now demanding fresh approaches to AD research be funded, in addition to the older standbys of amyloid plaques and protein tangles.

Alzheimer’s Germ Quest, Inc. is a public benefit corporation headquartered in Naples Florida. Its mission is to accelerate and deepen scientific investigations into the possible role of infectious agents as the root cause of Alzheimer’s disease. It is the sponsor of the $1 Million Alzheimer’s Germ Quest Challenge Award for scientists. (ALZgerm.org).

Mollie Page
Page Print Communications
2397777243
email us here


Source: EIN Presswire

Providing Additional Knowledge to Help Improve Your Immune System by Dr. Susana Trujillo

Best Fucoidan

Best Fucoidan Product

Best Fucoidan Extracts

Cancer is as unique as each of the affected body tissues and the person who faces it.

You should not use this information to diagnose or treat any health problems or illnesses without consulting your physician. Please consult a doctor with questions you may have about your condition.”

— Dr. Susana Trujillo

NEW YORK, NY, UNITED STATES, July 12, 2018 /EINPresswire.com/ — Nutritional knowledge to help improve your immune system by Dr. Susana Trujillo

Cancer is as unique as each of the affected body tissues and the person who faces it. Therefore, Dr. Susana’s mission is to help you improve your condition by providing you with additional educational knowledge that will help you reinforce your immune system to fight cancer.

Because it is a long process, and more of a sustained effort on many levels of your awareness you must incorporate a wise and very detailed strategy to overcome the inner conflicts and frictions that are debilitating your immune system, which is your vital force. To heal from an advanced cancer, you need to regain as much energy as possible from all the aspects of your life. It requires inner reassessments in order to regain optimal health and functioning. For example, one benefit of brown seaweed nutrition is the Fucoidan content. Fucoidan is another much needed natural ingredient to help with energy levels, and contributes to a reduction in tiredness and fatigue.

As for what I consider to be the physical supplies, the basics are: good clean food, water, air, sunlight, shelter, meaningful work and relationship to the human community and rest. In recent years, many compassionate suppliers and professionals have been helping to improve the quality and availability of these basics. Since the most effective tools for improving health are often concentrates of foods or minerals, and many powerful therapies apply specific forms of these other provisions for health, I count myself among that group.

Specific protocols for different cancers are as complex and multifaceted as the caring professionals who devise them. Every year alternative-minded healers have grown in sophistication and effectiveness.

Following are some understandings about cancer that many health professionals agree upon:

· The toxic chemicals that enable much of our modern lifestyle are often found to have slight hormonal effects, and these are usually estrogenic. A comparison between the effects of estrogen on any vertebrate and the effects of a malignant cancer would highlight many parallels.

· Cancer thrives in a glycolysis environment, where the energy it needs is produced from the breakdown of sugar. Cancer declines or fails to thrive when cellular respiration is primarily the oxygen-rich metabolic event known as the Krebs Cycle.

· Chronic sustained stress and trauma to a cell, tissue, or organ will dramatically increase the likelihood of a cancer. This stress might be mechanical, chemical, or energetic. Chronic excesses of poor nutrition or deficiencies of necessary nutrients have caused this sustained stress and trauma for much of humanity and its history.

· Re-establishing the parameters of healthy balance, which our ancestors described as “aligning with natural law,” will enable any living being to recover from disease and regain health; that is, if there is reasonable time and vital energy to work with.

· When a cancer is diagnosed, the energetics of health for that person and the affected tissue should be understood by the diagnosing provider.

· The physician or health professional who diagnoses cancer should also explain these factors to patients and family members who are concerned. If this is not your experience with cancer treatment, keep looking.

Dr. Susana’s Anti-Cancer Natural Supplies

Below I am attaching a partial list of some natural ingredients scientifically proven to help manage common symptoms associated with anaerobic disorders. These include ingredients that can support the immune system to control the side effects caused by the treatments.

1. NatureMedic™ Fucoidan powered with AHCC®—This innovative product contains Fucoidan extracted from brown seaweeds, which contribute to apoptosis within the cancer cell according to reports from Japanese and Russian researchers. Other effects most noted are the protection of the patient’s digestive functions and alternative benefits for the thyroid metabolism. It also contains a healthful ingredients known as AHCC® (Active Hexose Correlated Compound) to more widely support the immune system and antioxidant activity in people who consume it as directed.

What makes this brand different for other Fucoidan brands?

From the idea to the finished product, this dietary supplement is considered a premium brand. NatureMedic™ Fucoidan was optimized with AHCC® to support and improve the Quality of Life of many people. This brand uses TWO species to extract the Fucoidan from: MOZUKU AND MEKABU (WAKAME). NatureMedic™ Fucoidan powered with AHCC® contains CERTIFIED ORGANIC FUCOIDAN extracted from the MEKABU SPORES. This means that you do not have to question the fact that these products might be contaminated.

​Besides Fucoidan, it also contains two mushroom extracts: Agaricus blazei Murill and AHCC® (Active Hexose Correlated Compound). Fucoidan powered with AHCC® is an exclusive and innovative blend that combines high-quality Fucoidan extracted from Okinawa Mozuku and Australian Mekabu Fucoidan. This unique combination contains AHCC®, a cultured mushroom mycelia extract that is rich in alpha glucans.

2. Iodine—This is a remarkable “smart mineral” which has been widely known as deficient in most Americans for many years. This form is a well-studied and absorbable form of Iodine, and it’s another affordable and effective support for complex conditions of metabolic imbalance.

3. DIM—Di-Indoly Methane (DIM) is a gift from the cabbage plant family that is proven to help the liver metabolize estrogens into beneficial byproducts.

4. Calcium D-Glucarate—This is a highly absorbable version of Glucaronic acid, which helps the liver with Phase 2 detoxification tasks–the specific pathway most challenged by complex petrochemicals and pollutants.

5. Vitamin D3—This “sunshine” vitamin is extensively referenced in medical literature as being protective of blood calcium levels. It is also proven to contribute to the protection of hormone levels in the blood, as well as the defense against some cancers.

The many various cancer types and locations require specific support for their respective organ functions and protection from stress. This support can be achieved by the intelligent use of many natural foods and products.

Dr. Susana Trujillo
Dr. Susana Trujillo
2134788815
email us here

Best Fucoidan Products


Source: EIN Presswire

Adaptive Computing Changes Product Name from “Moab” to “Moab Cloud for the HPC Suite”

The name change more accurately describes the product’s new capabilities.

More than 2400 companies are interested in our Moab Cloud Solution, and we’re performing several Test Drives of the product every week”

— Arthur Allen, President & CEO, Adaptive Computing.

NAPLES, FL, UNITED STATES, July 12, 2018 /EINPresswire.com/ — Adaptive Computing Enterprises, a world leader in dynamically optimizing large-scale HPC computing environments, announced that it has changed the name of its flagship software product “Moab” to “Moab Cloud for the HPC Suite.” The new name more accurately reflects the product’s additional cloud-bursting capabilities.

For more than 10 years, administrators have relied on Moab more than any other HPC workload management solution because of its demonstrated ability to optimize scheduling and accelerate the workload productivity of their systems. It is currently in use at the largest and most complex high-performance computing environments in the world, including many leading commercial and innovative research HPC systems.

Moab Cloud for the HPC Suite adds a new level of benefits for HPC ecosystems by combining the time-tested elements of Moab with advanced cloud-bursting capabilities. The new solution can “burst” additional workloads to an external cloud on-demand. It is easy to use, manage, and configure and integrates with on-premise resources. It offers full stack provisioning, is automated, and is very cost-effective for customers.

Adaptive Computing Enterprises was acquired in September 2016 by software mogul Arthur L. Allen, a long-time industry veteran who has been creating software companies and technology solutions for 40 years. The company has been totally transformed through millions of dollars of investment in development, taking Moab to the next level. Adaptive Computing will continue to lead the market through product innovation, product quality and extraordinary customer support.

“More than 2400 companies are interested in our Moab Cloud Solution, and we’re performing several Test Drives of the product every week,” Allen said.

Combining the capabilities of public clouds with on-premise infrastructure brings unparalleled flexibility and scalability to the business. Moab Cloud for the HPC Suite has evolved into the premiere, best-in-class solution offering increased agility, cost reduction and unprecedented productivity.

About Adaptive Computing

Adaptive Computing manages some of the world’s largest computing installations. Our leadership in IT decision engine software has been recognized with over 45 patents and over a decade of battle-tested performance resulting in a solid Fortune 500 and Top500 supercomputing customer base.

Adaptive Computing’s mission is to bring higher levels of decision, control, and self-optimization to the challenges of deploying and managing large and complex IT environments, so they accelerate business performance at a reduced cost.

For more information, contact Sue DeGram, Director of Marketing at Adaptive Computing Enterprises Inc.

Sue DeGram
Adaptive Computing Enterprises Inc.
2393306083
email us here

Moab/NODUS Cloud Bursting Presentation and Demo


Source: EIN Presswire

Critically Important Book Released on Opioid Crisis by Simon A. Zysman, Ph.D.

 Successful Heroin and Opioid Addiction Treatment,

Successful Heroin and Opioid Addiction Treatment,

 Successful Heroin and Opioid Addiction Treatment,

Successful Heroin and Opioid Addiction Treatment,

Details treating addiction with high rate of success using breakthrough approach; includes contributions from several other specializing professionals.

The idea of treating addiction with only behavioral intervention is outdated and ineffective…you're not doing justice to the patient by giving them the least workable option,”

— Simon A. Zysman, Ph.D.

COMMACK, NEW YORK, UNITED STATES, July 11, 2018 /EINPresswire.com/ — NEW YORK, NY – Dr. Simon Zysman is one of the nation's most prominent and well known clinical psychologists in the treatment of the addiction to heroin and opioids (the most commonly prescribed pain medication).

In Successful Heroin and Opioid Addiction Treatment, announced today, Dr. Simon A. Zysman shares his vast experience in recovery treatment as well as a deep look into his incredibly effective treatment program setting former addicts upon a positive road to recovery and a productive future. Opioid dependency is currently considered a lethal epidemic that has run rampant throughout the United States. The spread of opioid addiction is shockingly more by medical doctors inadvertently over-prescribing highly-addictive painkiller medication to their patients as opposed to illegal drug dealers. Dr. Zysman's success in treating this vicious addiction goes against the grain when it comes to the techniques utilized by many recovery specialists.

Dr. Zysman's reputation is such that he was invited to address the New York State Senate Task Force on Heroin and Opiate Addiction on his groundbreaking treatment methodology. It was there Dr. Zysman was asked to write a book about the approach. Thus, a two-year effort began that has culminated in the publication of Successful Heroin and Opioid Addiction Treatment, an amazing look at the vitally important work of Dr. Zysman.

This book released also includes contributions from several specializing medical professionals such as Steven J. Blander, M.D. Board Certified in Internal Medicine and Infectious Disease, Melinda T. Del Castillo M.D. Psychiatrist and Addition Medicine, Regina Neuman, M.D. Internal Medicine and Addiction Medicine, Steven M. Silverman, M.D. Board Certified in Addiction Medicine, Isabel M. Tolentino-Marasol, M.D. Board Certified Psychiatrist and Addiction Medicine, Farhaana Zainul, J.D., CASAC Health Law and Quality Assurance, Jacqueline P. Zysman-Weisfeld, Pharm. D. Pharmacist, Matthew L. Zyzman, LMSW Clinical Social Worker and Addiction Specialist.

For more information about Employee Assistance Resource Services, Inc., located in Smithtown Long Island, visit https://www.earsrecoveryprogram.com and for information on ordering a copy of the book, Successful Heroin and Opioid Addiction Treatment, please visit http://www.simonzysman.com.

Media related inquiries with the Doctor, bookings, interview requests, etc., can be directed to John Colascione, Long Island Media Inc., 67 Harned Road, Commack, NY 11725, Phone: 631-406-4410.

JOHN COLASCIONE
Long Island Media Inc.
631-406-4410
email us here


Source: EIN Presswire

Integrative Healer Shirley Furman to be Featured on CUTV News Radio

IRVINE, CALIFORNIA, UNITED STATES, July 11, 2018 /EINPresswire.com/ — Creating new habits can be extremely difficult if not impossible. We will often avoid change until we have no other choice. Fortunately, the healthy version of you is not the exception to the rule; there are fundamental tools we all have at our disposal to create new habits and live the healthy life we were born to live.

Shirley Furman is a nurse practitioner and integrative healer. Integrative healers provide healthcare with a focus on the whole person, using different methods to meet the specific needs of the client.

“I love what I do as a nurse practitioner and I love being able to use medication to help people who need it,” says Furman, “but after doing this for 20 years, I’ve found a lot of people use antidepressants and even tranquilizers to help with anxiety or depression, when they just need healthier, less expensive, tools to improve their health. My goal is to give people as many of the fundamental tools and habits so they can get off their meds or not even start them.”

According to Furman, a vast majority of our issues are actually the result of sleep deprivation. She helps her patients reclaim their health and wellness through a combination of hypnotherapy and sleep restoration.

“Sleep is something we're born doing, we take it way too much for granted,” says Furman. “So let's try the simple solutions first. Restful sleep can be a bigger life changer than exercise or nutrition. When you're not getting enough sleep, you're more vulnerable. With adequate sleep you make better decisions. It’s a great integrative tool and it’s free!”

Most of us can be successful for short periods, but the biggest challenge is maintaining it after we’re reached our goal and working it into our lifestyle. Furman says hypnotherapy can help ease that transition by connecting with our subconscious.

“Medicine can change people's lives, but if there's a way to take care of the problem without medication, then I'm all for it. I believe in the power of hypnotherapy because it is so fast and powerful,” says Furman. “The goal is to develop new habits and incorporate them into our lifestyle, but we tend to ignore our subconscious. With hypnotherapy I find I can change my patient’s lives faster and easier with no side effects.”

CUTV News Radio will feature Shirley Furman in an interview with Jim Masters on July 11th at 4pm EDT.

Listen to the show on BlogTalkRadio.

If you have a question for our guest, call (347) 996-3389.

For more information on Shirley Furman, visit www.integrativehealer.com

Lou Ceparano
CUTV News
(631) 850-3314
email us here


Source: EIN Presswire

Major Upgrade for Patentcloud Announced by InQuartik

Quality Insights provides a deeper dive into the quality of a patent.

Patentcloud is proud to present the new Quality Insights.

InQuartik unveils a major upgrade for Patentcloud, with the new Quality Insights and claim-chart formatted Prior Art Comparison, among other enhancements.

Patentcloud’s upgrades, in particular Quality Insights and its new Prior Art Comparison, are truly a breakthrough for the patent litigation and transaction markets.”

— Leon Hsu of InQuartik

TAIPEI, TAIWAN, TAIWAN, July 11, 2018 /EINPresswire.com/ — InQuartik, a global software company, has announced a major upgrade to Patentcloud, its AI-powered patent intelligence platform. These new enhancements have come together to make Patentcloud even more powerful—and even more user-friendly.

At the top of the list is the new Prior Art Comparison. This exciting new feature quickly aligns the claims of a patent to the prior art in the prosecution and then displays the results in an easy-to-read claim-chart format.

As a better index for reading all of the claims, the new Prior Art Comparison feature enables users to better understand not only the relationship of the prior art to the claims but also the context and examiner’s opinions. With it, users can immediately understand the difference between the claimed invention and the prior art in the prosecution—in other words, the gist of the invention, which can also benefit claim construction.

Prior Art Comparison is one of the new features in what is now called Quality Insights (formerly Validity Insights). This new name reflects how this product now delivers insights not only into the validity but also the quality of a patent at a deeper level.

Quality Insights also now has a convenient Family Prior Art feature, which includes patent family data from the USPTO as well as from the other IP5 offices and WIPO. With all of the family prior art consolidated in one comprehensive overview and the§102 and 103 citations highlighted, users can save time and quickly focus their attention on their validity/invalidity evaluations.

Another Patentcloud product, Patent Search, has received an upgrade of its own to the technical architecture of its Project feature. This improvement has not only optimized performance, but it also includes a new user interface.

In addition, with My Folder, Patent Search basic users can manage up to 2,000 patents in 20 folders, with up to 10 file levels. Premium users also have access to My Folder, plus an additional Project, in which they can manage up to 100,000 patents in 1,000 folders, with up to 10 file levels.

The new Project feature also facilitates collaboration among a wide range of people, from patent professionals to engineers, by enabling premium users to share analysis results with basic members.

“Patentcloud’s upgrades, in particular Quality Insights and its new Prior Art Comparison, are truly a breakthrough for the patent litigation and transaction markets, since they make the quality of patents transparent in just a few clicks,” said Leon Hsu, director of Product Development at Patentcloud. “And the new enhancements to the Project feature are enabling higher performance and even greater collaboration and sharing of information, enabling Patentcloud, in turn, to become a collaborative workspace for patent professionals and their stakeholders.”

To learn more about Patentcloud and these exciting new upgrades, visit www.patentcloud.com, or to try these new products and features yourself, visit app.patentcloud.com.

***
Patentcloud is a patent intelligence platform that leverages artificial intelligence and big data analytics for better business decisions. Patentcloud delivers actionable insights through its three products—Quality Insights, Patent Search, and Design Search.

InQuartik is a global software company that specializes in artificial intelligence and big data analytics. With a mission to organize key data and discover business insights for impactful decisions, InQuartik utilizes high-quality data, innovative software, AI technology, and big data analytics to derive wisdom from data to empower the world. Find out more about InQuartik at www.inquartik.com.

Ted Pigott
InQuartik
886-2-7733-0277
email us here


Source: EIN Presswire

Goliath Resources Commences 2018 Exploration, Highly Prospective for Major Gold and Copper Discovery, Golden Triangle BC

Goliath’s Prosperity Bullseye Zone

11 metre Copper and Silver sample open at surface

GOT.V projects proximal to Golden Triangle

When drilling begins Goliath Resources Ltd. (TSX-V: GOT) (Frankfurt: B4IE) will start in high-grade mineralization, the only question is how deep and what grade

Goliath Resources Limited (TSX:GOT)

Goliath Resources has recently been the subject of several advisories, including mining analyst Bob Moriarty and Portfolio Manager John Newell of Fieldhouse Capital Management.”

— MMW Journal

NEW YORK, NY, USA, July 11, 2018 /EINPresswire.com/ — Goliath Resources Limited (TSX-V: GOT) (Frankfurt: B4IE) announced the initiation of its surface exploration programs on both its Copperhead and Lucky Strike properties located proximal to the Golden Triangle in British Columbia. The Company is planning to drill highly prospective virgin targets this 2018 which were previously under glaciers that only recently retreated, exposing exceptional Gold, Silver, and Copper mineralization at surface.

The following URLs have been identified for further insight on Goliath Resources Ltd.:
– Company website:
https://goliathresourcesltd.com
– Recent Mining MarketWatch Journal article:
http://miningmarketwatch.net/got.htm
– Recent CEO Interview:
http://sectornewswire.com/release070618got.htm

Goliath Resources Founder and CEO, Roger Rosmus, was interviewed recently by Dr. Allen Alper, PhD Economic Geology and Petrology, Columbia University, NYC (we have provided excerpt copy of interview below). Goliath Resources has recently been the subject of several advisories, including mining analyst Bob Moriarty and Portfolio Manager John Newell of Fieldhouse Capital Management, regarding exceptional valuation-creation potential as the Company prepares to drill two of its four properties this summer-2018 proximal to the Golden Triangle in British Columbia. A very real possibility exists for investors to experience a major appreciation in share price when Goliath announces initial drill results. Analogies for what GOT.V investors have potential to see are what happened to the share prices of GT Gold Corp. (TSX-V: GTT $0.20 to $2.76) and Garibaldi Resources Corp. (TSX-V: GGI $0.20 to $2.76) when they hit their discovery drill holes in 2017.

Interview excerpt:
Goliath Resources Limited (TSX-V: GOT, Frankfurt: B4IE) is a project generator of precious metals projects, focused in the prolific Golden Triangle and surrounding area of northwestern British Columbia. It controls 100% of four highly prospective properties that include Bingo, Golddigger, Lucky Strike and Copperhead, covering over 44,000 hectares. All four properties have brand new discoveries, never drilled before, that all have returned anomalous gold, silver and/or copper in soils, grab and channel samples from exposed bedrock at surface over large areas. We learned from Roger Rosmus, Founder and CEO of Goliath Resources Limited, a veteran investment banker, that as project generator, they are looking for projects that are elephant size, that are new and that will tick all the boxes for any senior mining company to do a joint venture, a strategic investment, or a potential takeout. Their new discoveries are the product of glacial recession and permanent snowpack melting due to the recent climate change resulting in widespread hybrid mineralization at surface over large areas seen for the first time; truly a once in a life time event. The main focus, in 2018, includes drilling of brand new discoveries at their Lucky Strike and Copperhead projects

Dr. Allen Alper: This is Dr. Allen Alper, Editor-in-Chief of Metals News, interviewing Roger Rosmus, the Founder and CEO of Goliath Resources. Could you give our readers/investors an overview of yourself, your company, your focus and current activities?

Roger Rosmus: I've been in the investment banking world for over 25 years, primarily raising capital for private and public companies, many have been in the resource sector. When I saw this package of assets, I literally fell off my chair, in awe, because this is a once in a life time opportunity. I've never seen anything so spectacular as these four projects in my entire career that also have similarities to GT Gold Corp. (TSX-V: GTT) and Garibaldi Resources Corp. (TSX-V: GGI) projects before they drilled.

After the company was incorporated, we raised 2.2 million dollars and completed a RTO transaction in October of 2017. We are currently trading on the TSX venture, under the symbol GOT, and more recently, we listed on a Frankfurt, the ticker being B4IE. With the 2.2 million raised, we took options on four projects in the golden triangle and surrounding area from the J2 Syndicate, a private company and precious metals project generator. Golddigger and Bingo projects are within the triangle, and we have two projects, just south of there, around Terrace & Smithers, BC, which are Lucky Strike and Copperhead.

In addition to taking the four property options, we also acquired a 10 percent interest in a private syndicate called DSM, which staked six projects far south of Terrace. Goliath will receive 10 percent of all the economics in relation to any deals on these projects, that could potential provide non-dilutive cash flow for the company down the road.

Our business model is purely a project generator of precious metal projects that are new discoveries and elephant size. We are looking for new large projects in the right geological setting that will tick all the boxes for any senior mining company to do a potential joint venture, strategic investment, or a potential takeout. If they don’t tick all the boxes, we're not going to waste our time on it. As we all know, grass roots exploration is a high-risk business, and we’ll do anything to help mitigate some of these risks. We're looking for new discoveries that are highly mineralized, large and obvious, which we have found at all four projects. Attracting a senior partner increases the probability of success and getting a material project across the line. We do believe that there is the potential to have one or even two significant discoveries this year. The first being our massive Prosperity Bullseye Gold-Copper-Moly porphyry drill target at Lucky Strike and our large area of volcanic breccia outcrop that has widespread mineralization of Copper-Silver exposed at surface at Copperhead…

The full CEO interview may be viewed at http://sectornewswire.com/release070618got.htm online.

Articles, excerpts, commentary and reviews herein are for information purposes and are not solicitations to buy or sell any of the securities mentioned.

Fredrick William
Market Equities Research Group
8666209945
email us here

Goliath Resources’ Prosperity Bullseye Zone


Source: EIN Presswire